Sionna Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
Sionna Therapeutics, Inc. (SION)
Company Research
Source: GlobeNewswire
Phase 1 MAD dosing completed for SION-451 and final MAD cohort of SION-719 planned; Interim data in healthy volunteers show potential to provide clinically meaningful benefit to CF patients. Topline data anticipated in first half of 2025 On track to initiate NBD1 Phase 2a proof-of-concept trial in combination with SOC in CF patients and combination MAD trials of an NBD1 stabilizer with a complementary modulator in healthy volunteers in the second half of 2025, with topline data for both anticipated in mid-2026 Completed upsized IPO with gross proceeds of approximately $219 million, extending runway into 2028 WALTHAM, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmac
Read more
Impact Snapshot
Event Time:
SION
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SION alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SION alerts
High impacting Sionna Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SION
News
- Sionna Therapeutics, Inc. (NASDAQ: SION) is now covered by analysts at TD Cowen. They set a "buy" rating on the stock.MarketBeat
- Sionna Therapeutics, Inc. (NASDAQ: SION) is now covered by analysts at Guggenheim. They set a "buy" rating and a $45.00 price target on the stock.MarketBeat
- Sionna Therapeutics, Inc. (NASDAQ: SION) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating and a $32.00 price target on the stock.MarketBeat
- Sionna Therapeutics to Present at the 45th Annual TD Cowen Health Care ConferenceGlobeNewswire
- Sionna Therapeutics Announces Closing of $219.2 million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares [Yahoo! Finance]Yahoo! Finance
SION
Sec Filings
- 3/20/25 - Form 10-K
- 3/20/25 - Form 8-K
- 3/7/25 - Form SEC
- SION's page on the SEC website